Screening for vancomycin-resistant enterococci with Xpert® vanA/vanB: diagnostic accuracy and impact on infection control decision making

B J Holzknecht, D S Hansen, L Nielsen, A Kailow, J O Jarløv, B J Holzknecht, D S Hansen, L Nielsen, A Kailow, J O Jarløv

Abstract

Vancomycin-resistant enterococci (VRE) are increasingly important nosocomial pathogens and screening for colonization status is a mainstay in infection control. We implemented PCR-based screening during vanA-positive Enterococcus faecium outbreaks in four university hospitals in Copenhagen, Denmark. Xpert®vanA/vanB was performed directly on rectal swabs and the vanA PCR result was used to guide infection control measures. Concurrently, all samples were selectively cultured including an overnight enrichment step. Diagnostic accuracy was calculated as well as turnaround time and the impact of the earlier available PCR results on infection control decision making. In all, 1110 samples were analysed. The vanA PCR positivity rate was 13.8% and culture positivity rate was 15.2%. The diagnostic accuracy of the vanA part of the assay was high with a sensitivity of 87.1%, a specificity of 99.7%, and positive and negative predictive values of 98.0% and 97.7%, respectively. The vanB PCR had a considerably lower specificity of 77.6% and a positive predictive value of 0.4%. In 1067 (96.1%) samples, PCR results were reported within 1 day, whereas median culture turnaround time was 3 days. The saving of time to available results corresponded to 141 saved isolation days and 292 saved transmission risk days. False-negative or false-positive PCR results led to six additional transmission risk days and 13 additional isolation days, respectively. The vanA PCR had high diagnostic accuracy and the prompt availability of results gave a considerable benefit for infection control decision making.

Keywords: Infection control; PCR-based screening; molecular screening; selective culture; vanA; vancomycin-resistant enterococci.

Figures

Fig. 1
Fig. 1
Infection control algorithm and impact of vanA PCR results from 1110 samples on infection control measures. Left: infection control algorithm and sample indication (italicized); centre: sample count and results stratified by indication; right: impact on infection control decision making. aAdmission or transferral from non-outbreak wards (n = 9), follow-up sample after former discordant result (n = 1), unknown indication (n = 3).

References

    1. Leclercq R., Derlot E., Duval J., Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med. 1988;319:157–161.
    1. Uttley A.H., Collins C.H., Naidoo J., George R.C. Vancomycin-resistant enterococci. Lancet. 1988;1(8575-6):57–58.
    1. Werner G., Coque T.M., Hammerum A.M., Hope R., Hryniewicz W., Johnson A. Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill. 2008;13(47)
    1. Cetinkaya Y., Falk P., Mayhall C.G. Vancomycin-resistant enterococci. Clin Microbiol Rev. 2000;13:686–707.
    1. Cattoir V., Leclercq R. Twenty-five years of shared life with vancomycin-resistant enterococci: is it time to divorce? J Antimicrob Chemother. 2013;68:731–742.
    1. Mascini E.M., Bonten M.J. Vancomycin-resistant enterococci: consequences for therapy and infection control. Clin Microbiol Infect. 2005;11(Suppl 4):43–56.
    1. Gastmeier P., Schroder C., Behnke M., Meyer E., Geffers C. Dramatic increase in vancomycin-resistant enterococci in Germany. J Antimicrob Chemother. 2014;69:1660–1664.
    1. Bourdon N., Fines-Guyon M., Thiolet J.M., Maugat S., Coignard B., Leclercq R. Changing trends in vancomycin-resistant enterococci in French hospitals, 2001–08. J Antimicrob Chemother. 2011;66:713–721.
    1. Statens Serum Institut. EPI-NEWS No 16/17 – 2014. Available at: ; accessed 20 December 2016.
    1. Pinholt M., Larner-Svensson H., Littauer P., Moser C.E., Pedersen M., Lemming L.E. Multiple hospital outbreaks of vanA Enterococcus faecium in Denmark, 2012–13, investigated by WGS, MLST and PFGE. J Antimicrob Chemother. 2015;70:2474–2482.
    1. Muto C.A., Jernigan J.A., Ostrowsky B.E., Richet H.M., Jarvis W.R., Boyce J.M. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol. 2003;24:362–386.
    1. Weber S.G., Huang S.S., Oriola S., Huskins W.C., Noskin G.A., Harriman K. Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: position statement from the Joint SHEA and APIC Task Force. Infect Control Hosp Epidemiol. 2007;28:249–260.
    1. Faron M.L., Ledeboer N.A., Buchan B.W. Resistance mechanisms, epidemiology, and approaches to screening for vancomycin resistant Enterococcus in the health care setting. J Clin Microbiol. 2016;54:2436–2447.
    1. Birgand G., Ruimy R., Schwarzinger M., Lolom I., Bendjelloul G., Houhou N. Rapid detection of glycopeptide-resistant enterococci: impact on decision-making and costs. Antimicrob Resist Infect Control. 2013;2(1):30.
    1. Fang H., Nord C.E., Ullberg M. Screening for vancomycin-resistant enterococci: results of a survey in Stockholm. APMIS. 2010;118:413–417.
    1. Werner G., Serr A., Schutt S., Schneider C., Klare I., Witte W. Comparison of direct cultivation on a selective solid medium, polymerase chain reaction from an enrichment broth, and the BD GeneOhm VanR Assay for identification of vancomycin-resistant enterococci in screening specimens. Diagn Microbiol Infect Dis. 2011;70:512–521.
    1. Mak A., Miller M.A., Chong G., Monczak Y. Comparison of PCR and culture for screening of vancomycin-resistant Enterococci: highly disparate results for vanA and vanB. J Clin Microbiol. 2009;47:4136–4137.
    1. Marner E.S., Wolk D.M., Carr J., Hewitt C., Dominguez L.L., Kovacs T. Diagnostic accuracy of the Cepheid GeneXpert vanA/vanB assay ver. 1.0 to detect the vanA and vanB vancomycin resistance genes in Enterococcus from perianal specimens. Diagn Microbiol Infect Dis. 2011;69:382–389.
    1. Zabicka D., Strzelecki J., Wozniak A., Strzelecki P., Sadowy E., Kuch A. Efficiency of the Cepheid Xpert vanA/vanB assay for screening of colonization with vancomycin-resistant enterococci during hospital outbreak. Antonie Van Leeuwenhoek. 2012;101:671–675.
    1. Babady N.E., Gilhuley K., Cianciminio-Bordelon D., Tang Y.W. Performance characteristics of the Cepheid Xpert vanA assay for rapid identification of patients at high risk for carriage of vancomycin-resistant Enterococci. J Clin Microbiol. 2012;50:3659–3663.
    1. Stamper P.D., Cai M., Lema C., Eskey K., Carroll K.C. Comparison of the BD GeneOhm VanR assay to culture for identification of vancomycin-resistant enterococci in rectal and stool specimens. J Clin Microbiol. 2007;45:3360–3365.
    1. Bourdon N., Berenger R., Lepoultier R., Mouet A., Lesteven C., Borgey F. Rapid detection of vancomycin-resistant enterococci from rectal swabs by the Cepheid Xpert vanA/vanB assay. Diagn Microbiol Infect Dis. 2010;67:291–293.
    1. Gazin M., Lammens C., Goossens H., Malhotra-Kumar S. Evaluation of GeneOhm VanR and Xpert vanA/vanB molecular assays for the rapid detection of vancomycin-resistant enterococci. Eur J Clin Microbiol Infect Dis. 2012;31:273–276.
    1. Ballard S.A., Pertile K.K., Lim M., Johnson P.D., Grayson M.L. Molecular characterization of vanB elements in naturally occurring gut anaerobes. Antimicrob Agents Chemother. 2005;49:1688–1694.
    1. Graham M., Ballard S.A., Grabsch E.A., Johnson P.D., Grayson M.L. High rates of fecal carriage of nonenterococcal vanB in both children and adults. Antimicrob Agents Chemother. 2008;52:1195–1197.
    1. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Available at: .
    1. Szakacs T.A., Kalan L., McConnell M.J., Eshaghi A., Shahinas D., McGeer A. Outbreak of vancomycin-susceptible Enterococcus faecium containing the wild-type vanA gene. J Clin Microbiol. 2014;52:1682–1686.
    1. Thaker M.N., Kalan L., Waglechner N., Eshaghi A., Patel S.N., Poutanen S. Vancomycin-variable enterococci can give rise to constitutive resistance during antibiotic therapy. Antimicrob Agents Chemother. 2015;59:1405–1410.
    1. Jakobsen M., Skovgaard C.M.B., Jensen M.L., Wolf R.T., Rasmussen S.R. Det Nationale Institut for Kommuners og Regioners Analyse og Forskning (KORA); 2015. Omkostninger ved husdyr-MRSA for sundhedsvæsenet i Danmark. Available at: accessed 20 December 2016.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit